Table 3.
False-positive HPV types detected, by assay
| HPV assay | No. of data sets | HPV region targeted [(primer(s)] | No. of data sets with the following no. of false-positive samples: |
||||
|---|---|---|---|---|---|---|---|
| 0 | 1 | 2 | 3 | >3 | |||
| All assays | 132 | L1/L2/E1/E2/E4/E6/E7 | 71 | 12 | 19 | 4 | 26 |
| Linear Array (Roche) | 17 | L1 (PGMY) | 10 | 1 | 2 | 1 | 3 |
| InnoLiPA (Innogenetics) | 12 | L1 (SPF10) | 2 | 1 | 5 | 0 | 4 |
| In-house line blot | 10 | L1 (GP/PGMY) | 4 | 2 | 1 | 1 | 2 |
| CLART HPV 2/3 (Genomica) | 8 | L1 (PGMY) | 3 | 1 | 2 | 1 | 1 |
| In-house RFLPa | 7 | L1/E6/E7 | 4 | 1 | 0 | 1 | 1 |
| In-house PCR Luminex | 7 | L1 (GP/MGP/BSGP/PGMY) | 5 | 0 | 1 | 0 | 1 |
| In-house real-time PCR | 6 | L1/E1/E4/E6/E7 | 2 | 1 | 1 | 0 | 2 |
| PGMY-CHUV | 6 | L1 (PGMY) | 6 | 0 | 0 | 0 | 0 |
| In-house type-specific PCR | 6 | L1/E6/E7 | 2 | 0 | 2 | 0 | 2 |
| In-house PCR sequencing | 6 | L1/E6 | 3 | 2 | 0 | 0 | 1 |
| In-house HPV-16/18-specific PCR | 6 | E6/E7 | 4 | 1 | 1 | 0 | 0 |
| HPV-16/18 specific PCR (Lab.Bio) | 4 | L1/E6/E7 | 4 | 0 | 0 | 0 | 0 |
| Papillocheck microarray (Greiner Bio-One) | 4 | E1 | 4 | 0 | 0 | 0 | 0 |
| PCR Luminex (Multimetrix) | 3 | L1 (GP) | 3 | 0 | 0 | 0 | 0 |
| Digene HPV genotyping LQ (Qiagen) | 3 | L1 (GP) | 2 | 0 | 1 | 0 | 0 |
| Digene HPV genotyping RH (Qiagen) | 2 | L1 (GP) | 2 | 0 | 0 | 0 | 0 |
| Hybribio microarray | 2 | L1 | 0 | 0 | 1 | 0 | 1 |
| DEIA line probe (Lab.Bio) | 2 | L1 (SPF10) | 0 | 0 | 0 | 0 | 2 |
| In-house dot blot | 2 | L1 | 0 | 1 | 0 | 0 | 1 |
| LCD array (Chipron) | 2 | L1 (PGMY) | 2 | 0 | 0 | 0 | 0 |
| EASYChip (King Car) | 2 | L1 | 2 | 0 | 0 | 0 | 0 |
| Cobas 4800 (Roche) | 2 | L1 | 0 | 0 | 1 | 0 | 1 |
| Other commercialb | 10 | L1 | 5 | 1 | 1 | 0 | 3 |
| Other in-housec | 3 | L1/L2/E1/E2/E6 | 2 | 0 | 0 | 0 | 1 |
a
RFLP, restriction fragment length polymorphism.
b
Other commercial assays included the following, used by one laboratory each: Medical Device Microarray, PnE HPV genotyping Luminex, Ampliquality reverse hybridization, Panagene microarray, PANArray HPV, GenoFlow HPV array kit, MolGENTIX multiplex fluorescent PCR, Hybrid Capture 2, Sacace high-risk screen, and Genoserch HPV-31 Luminex.
c
Other in-house assays include the following, used by one laboratory each: in-house PCR enzyme immunoassay, in-house multiplex PCR gel analysis, and in-house mass spectrometry.